Genpharmasec Intrinsic Value
Genpharmasec (GENPHARMA) median intrinsic value is ₹2.82 from 2 valuation models (range ₹2–₹3), vs current price ₹1.13 — +149.6% upside (Trading Below Calculated Value), margin of safety 59.9%. For current market price and key ratios, visit Genpharmasec share price today.
GENPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Genpharmasec intrinsic value across 2 models vs current price ₹1.13 — upside/downside and value range per method. Browse GENPHARMA cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹2.82 | ₹2.54 - ₹3.10 | +149.6% | Book Value/Share: ₹11.82, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹2.26 | ₹2.03 - ₹2.49 | +100.0% | Revenue/Share: ₹24.00, P/S: 0.8x |
GENPHARMA Intrinsic Value vs Market Price — All Valuation Models
Genpharmasec fair value range ₹2–₹3 vs current market price ₹1.13 across 2 valuation models. Compare with GENPHARMA fair price to assess whether the stock is under or overvalued.
GENPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Genpharmasec median intrinsic value ₹2.82, current price ₹1.13 — Trading Below Calculated Value by 149.6%, margin of safety 59.9%.
What is the intrinsic value of GENPHARMA?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Genpharmasec (GENPHARMA) is ₹2.82 (median value). With the current market price of ₹1.13, this represents a +149.6% variance from our estimated fair value.
The valuation range spans from ₹2.26 to ₹2.82, indicating ₹2.26 - ₹2.82.
Is GENPHARMA undervalued or overvalued?
Based on our multi-method analysis, Genpharmasec (GENPHARMA) appears to be trading below calculated value by approximately 149.6%.
GENPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Genpharmasec financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.40 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.23 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -6.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.65x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GENPHARMA Cash Flow Quality — Operating & Free Cash Flow
Genpharmasec operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-5 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-3 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |